quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·9d
PRRelease
MeiraGTx Holdings plc logo

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

MGTX· MeiraGTx Holdings plc
Health Care
Original source

Companies

  • MGTX
    MeiraGTx Holdings plc
    Health Care

Recent analyst ratings

  • Nov 24UpdateH.C. Wainwright$20.00
  • Oct 21UpdateRaymond James$29.00
  • Jul 31UpdateChardan Capital Markets$36.00

Related

  • INSIDER8h
    Director Perceptive Advisors Llc was granted 555,555 units of Ordinary Shares (SEC Form 4)
  • INSIDER2d
    SEC Form 4 filed by Giroux Richard
  • SEC2d
    SEC Form 144 filed by MeiraGTx Holdings plc
  • SEC7d
    SEC Form 424B5 filed by MeiraGTx Holdings plc
  • SEC7d
    MeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • PR7d
    MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
  • SEC7d
    MeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR7d
    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022